Catherine Torralva
Family · San Antonio, TXNPI 1760854178
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,419, more than ten times the $33 reported in 2021. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- Novartis$1K
- Lilly USA, LLC$779
- UCB, Inc.$643
- Mallinckrodt Hospital Products Inc.$616
- plus $2K from 17 others
What the payments were for
- Food & beverage$8,30798%
- Education$2002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 87 | $1,869 |
| Johnson & Johnson | 54 | $1,361 |
| Novartis | 47 | $1,044 |
| Lilly USA, LLC | 28 | $779 |
| UCB, Inc. | 19 | $643 |
| Mallinckrodt Hospital Products Inc. | 25 | $616 |
| AstraZeneca | 27 | $509 |
| AbbVie | 5 | $392 |
| GSK | 14 | $319 |
| Pfizer | 13 | $212 |
| Fresenius Kabi USA, LLC | 6 | $160 |
| Genentech USA, Inc. | 9 | $153 |
| E.r. Squibb & Sons, L.L.C. | 6 | $124 |
| Ferring Pharmaceuticals Inc. | 4 | $58 |
| Radius Health, Inc. | 3 | $55 |
| Octapharma USA, Inc. | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $32 |
| Celltrion USA Inc. | 1 | $31 |
| Invivyd Inc | 1 | $24 |
| Sandoz | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,507 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 17 | $146,848 |
| Hydroxychloroquine Sulfate | 106 | $4,196 |
| Leflunomide | 52 | $3,719 |
| MethotrexateMethotrexate Sodium | 104 | $3,640 |
| Sulfasalazine DrSulfasalazine | 33 | $2,391 |
| Mycophenolate Mofetil | 15 | $1,600 |
| Duloxetine Hcl | 32 | $1,009 |
| Colchicine | 12 | $986 |
| Sulfasalazine | 18 | $468 |
| Gabapentin | 24 | $422 |
| Methylprednisolone | 58 | $359 |
| Prednisone | 56 | $232 |
| Folic Acid | 26 | $229 |
| Meloxicam | 22 | $161 |
| Allopurinol | 17 | $158 |
Paid to pharmacies, not to this prescriber.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Febbie PhiriSan Antonio$31K
- Annette GantzSan Antonio$31K
- Renee ChisumSan Antonio$28K
- Thimios PartalasSan Antonio$27K
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.